Precision Medicine

The biotech firm's new genomic intelligence platform aims to de-risk development by providing the first-ever benchmarks for chromosomal integrity.

VectorBuilder tackles key AAV therapy hurdles in ophthalmology, aiming to boost consistency and unlock new treatments for blinding genetic diseases.

A new collaboration leverages a vast cord blood bank and advanced AI to create off-the-shelf cell therapies, promising a new era in regenerative medicine.

PVP Labs' new drug offers potent pain relief without addiction risk. A landmark DEA ruling clears it as a non-controlled substance, set to reshape medicine.

A new imaging agent could slash the years-long diagnostic delay for endometriosis, offering hope to millions of women suffering from the debilitating condition.

New research challenges long-held beliefs, revealing a high-risk subset in "safe" tumors and a surprising link between body weight and cancer recurrence.

South Korea approves its first homegrown CAR-T therapy, a landmark achievement offering new hope for lymphoma patients with impressive response rates.

New Phase III data shows a dual-action drug delivers significant weight loss while targeting liver health, positioning it as a major new player in the market.

TRexBio has dosed the first patient in a new trial for its novel drug, TRB-061, which aims to rebalance the immune system to treat atopic dermatitis.

Imviva Biotech's new CAR-T therapy shows potential for durable remission in lupus, moving advanced cell treatments beyond cancer to autoimmune disease.

With patient enrollment accelerating for its novel lung fibrosis drug, LTI-03, Rein Therapeutics signals progress in a field desperate for new options.

A new FDA-cleared system from Chest Wall Innovations offers both PEEK and titanium implants, promising surgeons unprecedented versatility in treating rib fractures.

A new partnership brings mask-free sleep apnea therapy to veterans, aligning with updated DoD/VA guidelines that prioritize patient preference and comfort.

Genomics' big data and Greywolf's novel drugs unite to develop first-in-class treatments for autoimmune diseases, promising a new era of precision medicine.

A landmark study reveals a hidden genetic cause for a common kidney disease in adults, urging for expanded genetic screening and paving the way for new therapies.

A new interactive lab and large-scale survey aim to combat pervasive gum disease. How does this data-driven approach fit into Hong Kong's public health landscape?

With financials improving but competition rising, medical device maker Pulmonx faces a critical audience at the BofA healthcare conference in May.

A new HHS agenda reopens the door for controversial peptides, just as a wave of next-gen obesity drugs threatens to upend the entire market.

A new therapy programs immune cells inside the body to fight disease. Sail Biomedicines is pioneering this approach to offer a potential cure for autoimmunity.

A new grant from Zymo Research aims to solve a key data problem in gut science, potentially unlocking the next wave of breakthroughs in personalized medicine.